All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The FDA has cleared an IND for a clinical trial in the U.S. of NBL-020, a fully human antibody drug independently developed by CSPC Pharmaceutical Group Ltd.'s subsidiary Novarock Biotherapeutics Ltd., for the treatment of advanced solid tumors.